|
EMC |
5 |
10/24/2003 |
Dr.
P. King |
Dr.
P. King |
|
|
|
C |
14 |
08/13/2003 |
Active
Pharmaceutical Ingredients Committee CEFIC/APIC
|
Pieter
van der Hoeven |
|
|
pdf |
C |
13 |
07/25/2003 |
Pharmaceutical Research and Manufacturers of America (PhRMA)
|
Alice
E. Till, PhD |
|
|
txt,
Attachment |
C |
12 |
07/14/2003 |
Bristol-Myers Squibb Pharmaceutical Research Institute
|
Laurie
F Smaldone, MD |
|
|
pdf |
EC |
3 |
06/24/2003 |
Farag,
S |
Farag,
S |
|
|
html |
EC |
2 |
06/17/2003 |
Richardson,
K |
Richardson,
K |
|
|
html |
EMC |
4 |
06/25/2003 |
Merck
& Co., Inc. |
David
W. Blois, PhD |
|
|
txt,
Attachment |
C |
11 |
07/02/2003 |
GlaxoSmithKline
(GSK) |
Mary
Faye S. Whisler, PhD |
|
|
pdf |
C |
10 |
06/30/2003 |
Number
Not Used |
|
|
|
|
C |
9 |
06/26/2003 |
Johnson
& Johnson Pharmaceutical research & Development, LLC
|
Sue
Halley |
|
|
pdf |
C |
8 |
06/25/2003 |
Novartis
Pharmaceuticals, Corporation |
Joan
A. Materna |
|
|
pdf,
Attachment |
C |
7 |
06/25/2003 |
Baxter
Healthcare Corporation |
Marcia
Marconi |
|
|
pdf |
C |
6 |
06/25/2003 |
International Assn for Pharceutical Science and Technology (PDA)
|
William
Stoedter, RAC |
|
|
pdf,
Attachment 1,
Attachment 2 |
C |
5 |
06/25/2003 |
Aventis
Pharmaceuticals, Inc. |
Steve
Caffe, MD |
|
|
pdf |
C |
4 |
06/25/2003 |
Centocor |
Thomas
M. Hogan |
|
|
pdf |
C |
3 |
06/17/2003 |
AstraZeneca
Pharmaceuticals, LP |
Norbert
R. Ealer |
|
|
pdf |
C |
2 |
06/03/2003 |
MedImmune,
Inc. |
Julia
Goldstein |
|
|
pdf |
C |
1 |
05/09/2003 |
Paul
G. King Consulting/FAME SYSTEMS |
Paul
G. King, PhD |
|
|
pdf |
EMC |
3 |
04/25/2003 |
Dr.
P. G. King |
Dr.
P. G. King |
|
|
|
EMC |
2 |
04/24/2003 |
Triangle
PEERS |
Lowrie
M. Beacham |
|
|
txt,
Attachment |
EMC |
1 |
04/24/2003 |
GlaxoSmithKline |
Amanda
Willcox |
|
|
txt,
Attachment |
EC |
1 |
02/22/03 |
Fine
Chemicals Corporation |
Dr.
Barratt Easter |
|
|
htm
|
NAD |
1 |
|
|
|
02/25/03
|
8772
|
pdf,
htm |
GDL |
1 |
02/20/03 |
Draft
Guidance |
|
|
|
pdf,
Word |
Top
| Up
Page last updated
March 29, 2004
|
|